Evidence map›Paper›PMID 41222596›Full record

ArticleCancer immunology, immunotherapy : CII2025

Generating CAR-macrophages to target endothelin B receptor-positive tumors.

Cyril Lherminier, Narciso Costa, Amaury Herbet, Marie Hautière, Aloïse Mabondzo, Jérémie Martinet, Didier Boquet

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cyril LherminierCEA, INRAE, Médicaments Et Technologies Pour La Santé (MTS), SPI, Laboratoire d'Etude de L'Unité Neurovasculaire Et Innovation Thérapeutique (LENIT), Université Paris-Saclay, 91191, Gif-Sur-Yvette, France.
Narciso CostaCEA, INRAE, Médicaments Et Technologies Pour La Santé (MTS), SPI, Laboratoire d'Etude de L'Unité Neurovasculaire Et Innovation Thérapeutique (LENIT), Université Paris-Saclay, 91191, Gif-Sur-Yvette, France.
Amaury HerbetCEA, INRAE, Médicaments Et Technologies Pour La Santé (MTS), SPI, Laboratoire d'Etude de L'Unité Neurovasculaire Et Innovation Thérapeutique (LENIT), Université Paris-Saclay, 91191, Gif-Sur-Yvette, France.
Marie HautièreCEA, INRAE, Médicaments Et Technologies Pour La Santé (MTS), SPI, Laboratoire d'Etude de L'Unité Neurovasculaire Et Innovation Thérapeutique (LENIT), Université Paris-Saclay, 91191, Gif-Sur-Yvette, France.
Aloïse MabondzoCEA, INRAE, Médicaments Et Technologies Pour La Santé (MTS), SPI, Laboratoire d'Etude de L'Unité Neurovasculaire Et Innovation Thérapeutique (LENIT), Université Paris-Saclay, 91191, Gif-Sur-Yvette, France.
Jérémie MartinetUNIROUEN, Inserm U1234, FOCIS Center of Excellence, Pan'THER, CHU de Rouen, Department of Immunology and Biotherapy, Normandie Université, 76000, Rouen, France.
Didier BoquetCEA, INRAE, Médicaments Et Technologies Pour La Santé (MTS), SPI, Laboratoire d'Etude de L'Unité Neurovasculaire Et Innovation Thérapeutique (LENIT), Université Paris-Saclay, 91191, Gif-Sur-Yvette, France. didier.boquet@cea.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The endothelin axis is highly involved and overexpressed in many tumors, making it an interesting therapeutic target. However, except for strategies based on small molecule antagonists, this axis is poorly targeted by immunotherapy approaches. Although cell-based therapies, in particular CAR-T cells, have produced impressive results in treating hematological tumors, they remain challenging for solid tumors. CAR-macrophages represent a promising alternative, but only a few therapeutic targets have been evaluated thus far. Having developed antibodies targeting ET1R, our laboratory proposes this axis as a target for CAR-macrophages development. This study investigated the efficacy of CAR-macrophages directed against the endothelin B receptor (ET

Indexed as

Immunotherapy, AdoptiveMacrophagesMelanomaReceptor, Endothelin BReceptors, Chimeric AntigenAnimalsCell Line, TumorHumansMiceXenograft Model Antitumor AssaysReceptor, Endothelin BReceptors, Chimeric AntigenCancerCAR-macrophagesChimeric antigen receptorEndothelin B receptorImmunotherapyMelanoma

Identifiers

PMID41222596
PMCPMC12612446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.